What Your Body Does And Doesn't Tell You About Your Kidneys
Credit: Daily Vitality
If you came here looking for the early symptoms of kidney disease, there's something you deserve to hear first, and it's a little uncomfortable: for most people, there aren't any. Not vague ones. Not subtle ones. None. Your kidneys can lose a substantial share of their filtering capacity while you feel completely, genuinely fine.
That's not a scare tactic. It's the single most useful thing to understand about this particular condition, and it reframes what you're actually looking for. An estimated 35.5 million American adults have chronic kidney disease, and according to the Centers for Disease Control and Prevention as many as nine in ten of them have no idea. Those millions of people aren't ignoring symptoms. They simply don't have any yet.
So the list below is real, and it's worth knowing. But it isn't an early-detection tool, and treating it like one is how people lose years they could have used. Think of these ten signs as the "worth a conversation soon" list rather than the "catch it early" list. They tend to appear once your kidneys have been struggling for a while.
The genuinely early detection happens somewhere less dramatic: a blood draw and a small cup of urine. Two ordinary tests, often already part of routine care for anyone with diabetes or high blood pressure, that can spot kidney damage long before your body registers a complaint. We'll walk through the warning signs, then spend real time on those tests, on what the stages mean, and on the treatment options — which have changed more in the last five years than in the three decades before them.
Your kidneys are remarkably over-engineered. Each one is roughly the size of a computer mouse, and together they filter all the blood in your body about every thirty minutes, pulling out waste and excess fluid while balancing minerals, supporting blood pressure, and signaling your bone marrow to make red blood cells.
That built-in surplus is exactly why damage hides. Healthy kidneys have far more filtering capacity than daily life requires, so as function declines, the remaining tissue quietly compensates. Waste products stay within normal range. Fluid balance holds. Nothing surfaces. By the time the reserve runs thin enough for you to actually feel something, a meaningful amount of function is usually already gone.
The National Institute of Diabetes and Digestive and Kidney Diseases puts it plainly: most people in the early stages have no symptoms, and many have none until the disease is advanced. Federal health guidance is equally direct that people with kidney disease may not feel ill at all, and that blood and urine testing is the only way to know for certain.
Here's the part that surprises people most. Unawareness doesn't just affect the early stages. Roughly 40% of adults with severely reduced kidney function who aren't yet on dialysis still don't know they have kidney disease. Silence isn't only an early-stage problem — it can persist remarkably far into the illness.
When kidneys can't clear excess fluid and sodium efficiently, that fluid has to go somewhere, and gravity decides where. It settles in the lowest parts of the body — ankles first, then feet and lower legs. Some people notice it as sock elastic leaving a deeper groove than it used to, or shoes that fit at breakfast and pinch by dinner.
Of all the symptoms on this list, swelling is the one federal guidance associates with kidney disease outside the advanced stages, and it can occasionally appear in the hands or face as well. Even so, the same guidance is careful to note that edema is more common when kidney disease is very advanced, or when a lot of protein is leaking into the urine.
Swelling has plenty of other explanations too — heart conditions, liver problems, certain blood pressure medications, inflammatory conditions such as rheumatoid arthritis, long flights, hot weather, or simply standing all day. That ambiguity is precisely why it isn't a reliable screening signal on its own. Persistent, unexplained swelling that doesn't resolve with rest and elevation is generally considered worth mentioning to a clinician, whatever the eventual cause turns out to be.
Urine that looks unusually foamy — the kind that lingers in the bowl rather than settling — can indicate protein escaping into it. Healthy kidneys hold protein back. Damaged filters let it slip through, and in sufficient quantity it changes how urine behaves, much the way a small amount of soap changes how water froths.
This is the one place where two respected authorities genuinely diverge, and it's worth knowing about rather than glossing over. The National Kidney Foundation describes foamy urine as potentially one of the first signs that kidneys aren't working as they should, while also cautioning that it has other causes and is easy to overlook. NIDDK, meanwhile, files foamy urine within its list of advanced kidney disease symptoms.
Both positions can be reconciled. Foam may reflect meaningful protein loss, and protein loss is one of the earliest measurable changes in kidney disease — but by the time there's enough protein to visibly foam, the leak is usually substantial. So it's a legitimate prompt for testing and a poor substitute for it. Fast urine streams and certain cleaning products produce bubbles too, which is part of why the urine albumin test exists.
Damaged kidneys can lose their ability to concentrate urine overnight, which means more trips to the bathroom in the small hours than used to be normal for you. Some people also notice increased frequency during the day, or urine that looks paler and more diluted than it once did.
The word doing the heavy lifting here is change. Everyone's baseline is different, and plenty of ordinary things shift it — an evening cup of tea, a new medication, a cold night. What tends to matter clinically is a pattern that's drifted from your own normal and stayed there.
It's also worth knowing that this symptom has strong competition. Urinary tract infections, an enlarged prostate, uncontrolled blood sugar, and diuretic medications all produce the same effect, and several are considerably more common than kidney disease. The National Kidney Foundation includes nighttime urination among its ten signs while noting these alternative explanations directly. Its presence doesn't point at your kidneys specifically — it points at something worth checking.
This is the symptom most consumer articles put first, and the physiology explains why it doesn't belong there. Healthy kidneys produce erythropoietin, a hormone that tells your bone marrow to manufacture red blood cells. As kidney tissue is damaged, less of that hormone gets made, fewer red blood cells circulate, and less oxygen reaches your muscles and brain. The result is a deep, heavy tiredness that a good night's sleep doesn't touch.
The timing is the key detail. According to NIDDK's guidance on anemia in kidney disease, anemia is less common in early kidney disease and generally worsens as the disease progresses, developing slowly and causing few or no symptoms at first. Most people with kidney failure have it; most people with early kidney disease do not.
So fatigue is genuinely a kidney disease symptom. It's simply a late one, arriving after enough tissue has been lost to disrupt hormone production. And because exhaustion accompanies nearly every condition in medicine — along with thyroid disorders, depression, sleep apnea, and conditions like fibromyalgia — it's among the least specific signals on this list.
When filtration slows, substances that would normally leave the body in urine remain in the bloodstream. That accumulation appears to interfere with sleep quality for many people with reduced kidney function, producing difficulty falling asleep, frequent waking, or sleep that simply doesn't restore.
There's a second, more specific connection worth knowing about. Sleep apnea occurs more frequently among people with chronic kidney disease than in the general population, and restless legs — that crawling, irresistible urge to move your legs at night — is also notably more common. Either can fragment sleep badly enough to produce daytime exhaustion that then gets attributed to something else entirely.
Like the others in this stretch of the list, disrupted sleep sits within the advanced-disease category rather than the early one. It also tends to arrive tangled up with the fatigue described above, which makes the two difficult to separate in practice and easy to write off together as stress, age, or a demanding stretch at work.
People sometimes describe it as reaching for a word that isn't there, rereading the same paragraph three times, or losing track mid-sentence. The mechanism runs mostly through the same anemia described earlier: less oxygen reaching the brain translates into slower, foggier thinking. Accumulating waste products in the blood appear to contribute as well.
Because it depends on anemia that develops late, concentration trouble is a downstream signal — a symptom of a symptom, in a sense. It shows up well after the kidney damage that eventually caused it, which is exactly why it can't function as an early warning.
It's also worth holding this one loosely. Difficulty concentrating accompanies poor sleep, stress, perimenopause, thyroid conditions, medication side effects, and ordinary overwork. On its own it says very little about your kidneys. Alongside several other items on this list, in someone with diabetes or high blood pressure, it forms a more meaningful pattern.
This isn't ordinary winter dryness. The itching associated with kidney disease is often widespread, persistent, and largely unresponsive to moisturizer — and it can be intense enough to disrupt sleep and daily life.
The explanation lies in mineral balance. Among their many jobs, healthy kidneys keep calcium and phosphorus in careful proportion. As function declines, phosphorus builds up in the blood, and that imbalance is thought to drive the characteristic itch. The National Kidney Foundation's guidance on the signs of kidney disease connects dry, itchy skin to exactly this kind of mineral and bone disturbance, which accompanies advanced disease when kidneys can no longer maintain the right balance of minerals and nutrients.
That physiological detail is what places this symptom firmly in the late category, despite how often it appears in online lists of early clues. Mineral imbalance severe enough to cause noticeable itching represents a substantial loss of kidney function, not the beginning of it.
As waste products accumulate in the bloodstream, many people notice food starting to taste different — often metallic — and meals becoming less appealing. Meat frequently goes first. Some people find they're eating noticeably less without having decided to, and unintended weight loss can follow.
Nausea and vomiting can accompany this, and all of these appear together on NIDDK's list of advanced kidney disease symptoms alongside weight loss and muscle cramps. The clustering isn't accidental. They share an underlying cause in the accumulation of substances that healthy kidneys would have cleared.
For anyone tracking their own health, the pattern here matters more than any single meal. Appetite fluctuates for countless reasons, from medications to mood to a stomach bug. A sustained shift — weeks of reduced appetite, a persistent taste change, or weight loss you didn't intend — is the version that generally warrants a conversation, whether or not kidneys turn out to be involved.
Cramping in the legs, particularly at night, can reflect the electrolyte disturbances that accompany declining kidney function. Calcium, phosphorus, potassium, and sodium all depend on kidney regulation, and when those levels drift, muscles can contract involuntarily and painfully.
This one carries a familiar caveat. Muscle cramps are extraordinarily common and usually have nothing to do with kidneys — dehydration, hard exercise, certain medications, pregnancy, and simple aging all produce them. Most people experience nighttime leg cramps at some point without any underlying disease at all.
What shifts a cramp from unremarkable to worth mentioning is context: frequency well beyond your normal, cramping that appears alongside other items on this list, or cramping in someone already known to be at elevated risk. In isolation, it's among the weakest signals here. It earns its place on the list mainly because it appears in the authoritative symptom set, not because it's independently informative.
Persistent puffiness around the eyes — most noticeable first thing in the morning — has a specific and somewhat surprising explanation. It can indicate that kidneys are leaking a significant quantity of protein into the urine rather than retaining it in the body, and the delicate tissue around the eyes shows the resulting fluid shift before most other places do.
Shortness of breath works through a different route, or rather two. Fluid that kidneys can't clear can accumulate in the lungs, making breathing feel effortful. Separately, the anemia described earlier reduces oxygen-carrying capacity, so you may feel winded climbing stairs that never used to register. Both mechanisms tend to appear in more advanced disease.
Shortness of breath in particular deserves a note of caution, because it belongs to several conditions that require prompt attention rather than a scheduled appointment.
New, sudden, or worsening shortness of breath — especially with chest pain, dizziness, or swelling that appears quickly — can signal a heart or lung emergency. That situation calls for immediate medical care rather than waiting to raise it at a routine visit.
Here's where the article turns from what you might notice to what can actually be found, and the shift is a meaningful one. Kidney disease is identified through two straightforward tests, and understanding what each one does explains why having both matters so much.
The first is a blood test that estimates your glomerular filtration rate, or eGFR — essentially, how much blood your kidneys filter per minute. NIDDK's guidance on kidney disease testing describes a GFR of 60 or above as within the normal range, below 60 as potentially indicating kidney disease, and 15 or below as kidney failure. It's calculated from a creatinine measurement along with your age and sex, and it typically appears on standard blood panels without anyone needing to request it specially.
The second test is where things get interesting, because it's the one that gets skipped. A urine albumin-to-creatinine ratio, usually shortened to uACR, measures how much protein is leaking through your kidneys' filters. Values of 30 mg/g or below are considered normal, and the National Kidney Foundation's explanation of uACR makes a point that reshapes how many people think about their results: a value above 30 mg/g can indicate kidney disease even when eGFR is above 60.
Sit with that for a moment. You can have a completely normal blood test result and still have chronic kidney disease, because protein leakage often precedes any measurable drop in filtration. Albuminuria is frequently the first thing to change. If only the blood test gets run, the earliest detectable evidence is the exact thing that goes unmeasured — which is arguably the most common way early kidney disease gets missed in ordinary care.
For anyone who wants a single concrete thing to take from this article, it might be this: many people at elevated risk have received an eGFR result without ever having had a uACR, and whether your last set of labs included the urine test is something you can simply ask about.
Lab results are usually available through a patient portal, and a uACR appears under names like "urine albumin/creatinine ratio," "microalbumin/creatinine," or "ACR." If you can find an eGFR but no urine albumin value, that's a reasonable thing to raise at your next appointment.
One more point about timing. A single abnormal result doesn't establish chronic kidney disease. The international KDIGO 2024 clinical practice guideline defines the condition as abnormalities of kidney structure or function present for a minimum of three months. Dehydration, infections, and certain medications can all temporarily depress kidney numbers, which is why clinicians generally repeat testing before applying a diagnosis. An unexpected result is a reason to retest, not a verdict.
Most people expect a stage to be one number. Kidney disease uses two, and understanding why makes the whole system more legible.
Staging combines the cause of the disease with a filtration category and an albuminuria category — the framework clinicians refer to as CGA. Filtration is graded G1 through G5, and protein leakage is graded A1 through A3. Your stage is the intersection of the two, which is why two people described as having "stage 3" kidney disease can face quite different outlooks depending on how much protein each is losing.
Two things are worth holding onto here. The first is that this framework is descriptive shorthand rather than a treatment instruction — it tells you and your clinician where you sit, not automatically what happens next. The second is more reassuring, and federal health guidance states it directly: not everyone with kidney disease progresses to kidney failure. Many people diagnosed at G2 or G3a, particularly with low albuminuria and well-managed blood pressure and blood sugar, remain stable for years or decades.
There's also a conversation available beyond the stage label. For people in categories G3 through G5, KDIGO guidance supports using a validated risk equation to estimate the actual probability of kidney failure over a defined period — a far more personal number than a stage. Whether that estimate has been calculated is something a nephrologist or primary care clinician can speak to.
One technical footnote that occasionally causes confusion: eGFR is an estimate, not a direct measurement, and current guidance advises against including race in that calculation. Some people whose results shifted when their lab updated its equation are seeing the effect of that change rather than a change in their kidneys.
Testing recommendations follow risk, and the risk factors are well characterized. The CDC's summary of kidney disease risk factors identifies diabetes, high blood pressure, heart disease, a family history of kidney failure, obesity, and older age as the principal ones, with regular testing advised for people in those groups.
Diabetes and high blood pressure deserve particular emphasis, because together they account for roughly two out of three new cases of kidney failure in the United States. If either applies to you, kidney monitoring isn't a separate concern layered on top — it's a standard component of managing the condition you already know about. Certain autoimmune conditions, including lupus, can also affect the kidneys directly and come with their own monitoring considerations.
Now for the honest complication. There is currently no United States Preventive Services Task Force recommendation on screening average-risk, asymptomatic adults for kidney disease. Its chronic kidney disease screening page is marked inactive, noting that the prior 2012 statement is out of date and that the topic is under evidence review.
That gap is narrower than it might sound, and it's worth being precise about what it does and doesn't mean. The open question concerns universal screening of the general population — whether everyone should be tested regardless of risk. It is not a question about people with diabetes, high blood pressure, or the other risk factors above, where testing is widely supported across kidney-focused guidance including CDC and KDIGO. If you're in a risk group, the disagreement doesn't apply to you.
This is the section that has changed most, and the part that makes early detection worth caring about. A diagnosis of chronic kidney disease today carries a substantially different outlook than the same diagnosis would have a decade ago. Treatment doesn't reverse existing damage — that's an honest limitation worth stating plainly — but it can slow progression considerably, and in many cases prevent kidney failure altogether.
Nearly everything else builds on this layer. CDC guidance on chronic kidney disease describes keeping blood pressure below 140/90 mm Hg or a clinician-set target, maintaining blood sugar within target range for people with diabetes, staying physically active, managing weight, following a kidney-friendly eating pattern developed with a dietitian, and stopping smoking. It also points toward a conversation with a doctor about ACE inhibitors and ARBs, blood pressure medications that appear to protect the kidneys beyond their blood-pressure-lowering effect.
Those two drug classes have a specific role in kidney care. KDIGO guidance supports them for people with kidney disease and albuminuria — non-diabetic kidney disease with severely increased albuminuria, and diabetic kidney disease with moderately or severely increased albuminuria — titrated to the highest approved dose that is tolerated. The same guidance advises against combining an ACE inhibitor with an ARB, which is a useful illustration that more medication isn't automatically better.
For adults aged 50 and older with kidney disease who aren't on dialysis or living with a transplant, KDIGO supports statin therapy, with a statin-ezetimibe combination considered when eGFR falls below 60.
The reasoning catches many people off guard. For most people with chronic kidney disease, the greatest threat isn't kidney failure — it's cardiovascular disease. Reduced kidney function substantially raises the risk of heart attack and stroke, which is why cholesterol management sits inside kidney care rather than beside it. If you're interested in that connection, our guide to the signs of poor heart health after 40 covers the cardiovascular side in more depth.
If one thing deserves your attention in this section, it's this class of drugs. SGLT2 inhibitors began as diabetes medications, and researchers noticed something unexpected in the trial data: they protected kidneys — including in people who didn't have diabetes at all.
Dapagliflozin was approved by the FDA in April 2021 for chronic kidney disease at risk of progression, in people with and without type 2 diabetes. In the DAPA-CKD trial published in the New England Journal of Medicine, it reduced the primary composite outcome of kidney disease progression and death by 39% compared with placebo. Empagliflozin followed in September 2023 with a similar indication, having reduced kidney disease progression or cardiovascular death by 28% in the EMPA-KIDNEY trial.
Current KDIGO guidance recommends an SGLT2 inhibitor for adults with type 2 diabetes and kidney disease at eGFR of 20 or above, and extends that to people with eGFR of 20 or above with significant albuminuria, or with heart failure regardless of albuminuria. Whether any particular person is a candidate depends on their filtration, albuminuria, other conditions, and existing medications — a question for a clinician rather than an article.
Finerenone represents a different mechanism, blocking mineralocorticoid receptors involved in kidney inflammation and scarring. The FDA approved it in July 2021 to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes. In the FIDELIO-DKD trial that supported approval, it reduced the composite kidney outcome by 18% and the cardiovascular outcome by 14%.
More recently, semaglutide — familiar to most people as a diabetes and weight management drug — gained an FDA label expansion in January 2025 covering reduced risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. That indication rests on the FLOW trial, in which semaglutide reduced major kidney disease events by 24%. Worth noting precisely: this applies to people who have both type 2 diabetes and kidney disease, not kidney disease alone.
For the minority of people whose kidney disease does progress to failure, dialysis and kidney transplantation are the treatments that take over filtration. Roughly 360 people in the United States begin dialysis each day.
It's worth framing these where they belong — as the outcome that everything above is designed to delay or prevent, not as the expected destination of a kidney disease diagnosis. Most people with chronic kidney disease will never need them.
Nothing here is a recommendation for any individual. Which treatments fit a particular person depends on their kidney numbers, other health conditions, current medications, and preferences — all of which is territory for a conversation with a clinician who knows your history.
About the Author
Angela Nightingale is a Senior Editor at Daily Vitality with over two decades of experience in digital publishing and health and wellness content. She specializes in turning complex, often-confusing health topics into clear, calm, and practical guidance that respects the reader's intelligence. Her work focuses on helping people feel informed and confident — never overwhelmed or alarmed — as they make everyday decisions about how they eat, move, rest, and age.
For most people, there aren't any. Early kidney disease is typically silent, and symptoms tend to appear only after substantial function has been lost. This is why blood and urine testing, rather than symptom-watching, is how early kidney disease actually gets found.
Yes, and it's the norm rather than the exception. Federal health guidance is explicit that people with kidney disease may not feel ill or notice anything at all. Around 40% of adults with severely reduced kidney function who aren't on dialysis remain unaware they have it.
No. Foamy urine can indicate protein leaking into the urine, but a fast urine stream, dehydration, and residual cleaning products in the toilet all produce foam as well. Persistent foaminess is generally considered a reason to test rather than a diagnosis.
A GFR of 60 or above is described as within the normal range, below 60 may indicate kidney disease, and 15 or below is classified as kidney failure. A single low result doesn't establish a diagnosis, since chronic kidney disease requires abnormalities present for a minimum of three months.
eGFR is a blood test measuring how much blood your kidneys filter. The urine albumin-to-creatinine ratio measures protein leaking through the filters. They detect different problems, and protein leakage often appears before filtration drops — so a normal eGFR alone doesn't rule out kidney disease.
Existing damage generally isn't reversible, but progression can often be slowed substantially, and in many cases kidney failure can be prevented entirely. Some acute kidney injury, which is a different condition, can resolve. The earlier chronic kidney disease is identified, the more of your remaining function there is to protect.
Regular kidney testing is advised for people with these conditions, and annual testing is common practice within diabetes and hypertension care. Specific intervals depend on prior results and overall risk, so the frequency appropriate for you is worth confirming with your own clinician.
No. Federal guidance states directly that not all people with kidney disease progress to kidney failure. Many people diagnosed at earlier stages, particularly with low albuminuria and well-managed blood pressure and blood sugar, remain stable for many years.
Adequate hydration supports kidney function and helps prevent kidney stones, but drinking large volumes of water doesn't reverse or prevent chronic kidney disease. For some people with advanced kidney disease or heart failure, high fluid intake can actually cause problems, which is why individual fluid targets are worth discussing rather than assuming.
That's the expected pattern rather than a contradiction. Kidney function changes are measured long before they're felt, which is the entire purpose of testing. Feeling well is genuinely good news, but it isn't evidence that lab values are stable.
Regular, heavy use of NSAIDs such as ibuprofen and naproxen can affect kidney function, particularly in people who already have reduced function or other risk factors. Occasional use is a different situation from routine daily use, and anyone with known kidney disease has reason to review pain relief options with a pharmacist or clinician.
